24 September 2025
Digital health and ocular data solutions company, Topcon Healthcare, has made an investment in Senseye, a US-based company aiming to develop a mental health diagnostic platform powered by ocular biomarkers.
Senseye technology uses artificial intelligence (AI) and computer vision to analyse ocular metrics, such as pupil dynamics and eye movement, captured through a smartphone camera.
This data is translated into validated digital biomarkers to support diagnosis and monitoring of post-traumatic stress disorder, major depressive disorder, and generalised anxiety disorder.
The agreement marks Topcon Healthcare’s first investment in technology for mental health.
Ali Tafreshi, CEO and president of Topcon Healthcare, described the Senseye technology as “providing objective, measurable mental health assessments from the eye.”
“Their work exemplifies our Healthcare from the Eye vision, expanding the role of ocular data beyond the eye and systemic disease into psychiatry. We are proud to support Senseye in accelerating their mission and see exciting opportunities for future collaboration,” Tafreshi added.
The companies suggest the Senseye solution could enable primary care clinicians, particularly in underserved communities, to identify and flag potential neuropsychiatric concerns and refer patients for further evaluation.
David Zakariaie, founder and CEO of Senseye, suggested the investment from Topcon is validation that “the eye holds the key to understanding the brain and mind.”
Topcon also suggested the collaboration could lay the groundwork for diagnostic modules on its connected care platform, Harmony, which currently integrates imaging, artificial intelligence analytics, and data sharing across clinical settings.
Comments (0)
You must be logged in to join the discussion. Log in